Diagnostic features of polycystic ovary syndrome
dc.contributor.author | Barday-Karbanee N. | |
dc.contributor.author | Siebert T.I. | |
dc.contributor.author | Botha M.H. | |
dc.contributor.author | Kruger T.F. | |
dc.date.accessioned | 2011-05-15T16:18:04Z | |
dc.date.available | 2011-05-15T16:18:04Z | |
dc.date.issued | 2006 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Review | |
dc.identifier.citation | South African Journal of Obstetrics and Gynaecology | |
dc.identifier.citation | 12 | |
dc.identifier.citation | 1 | |
dc.identifier.issn | 00382329 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/14498 | |
dc.subject | androstenedione | |
dc.subject | clomifene citrate | |
dc.subject | follitropin | |
dc.subject | gonadotropin | |
dc.subject | hydroxyprogesterone | |
dc.subject | luteinizing hormone | |
dc.subject | oral contraceptive agent | |
dc.subject | testosterone | |
dc.subject | thyrotropin | |
dc.subject | amenorrhea | |
dc.subject | androstenedione blood level | |
dc.subject | cancer research | |
dc.subject | cancer risk | |
dc.subject | cardiovascular disease | |
dc.subject | cardiovascular risk | |
dc.subject | clinical feature | |
dc.subject | clinical practice | |
dc.subject | consensus development | |
dc.subject | correlation analysis | |
dc.subject | cost effectiveness analysis | |
dc.subject | diagnostic accuracy | |
dc.subject | diagnostic value | |
dc.subject | disease association | |
dc.subject | endometrium cancer | |
dc.subject | endometrium carcinoma | |
dc.subject | estrogen blood level | |
dc.subject | female | |
dc.subject | follitropin blood level | |
dc.subject | genetic linkage | |
dc.subject | gonadotropin blood level | |
dc.subject | human | |
dc.subject | hyperandrogenism | |
dc.subject | hyperinsulinemia | |
dc.subject | hypertension | |
dc.subject | impaired glucose tolerance | |
dc.subject | incidence | |
dc.subject | insulin resistance | |
dc.subject | luteinizing hormone blood level | |
dc.subject | menopause | |
dc.subject | menstrual irregularity | |
dc.subject | metabolic syndrome X | |
dc.subject | non insulin dependent diabetes mellitus | |
dc.subject | nuclear magnetic resonance imaging | |
dc.subject | obesity | |
dc.subject | oligomenorrhea | |
dc.subject | ovary polycystic disease | |
dc.subject | pathogenesis | |
dc.subject | pathophysiology | |
dc.subject | phenotype | |
dc.subject | practice guideline | |
dc.subject | prediction | |
dc.subject | prevalence | |
dc.subject | race difference | |
dc.subject | review | |
dc.subject | risk assessment | |
dc.subject | risk factor | |
dc.subject | standard | |
dc.subject | statistical significance | |
dc.subject | testosterone blood level | |
dc.subject | three dimensional imaging | |
dc.subject | thyrotropin blood level | |
dc.subject | transvaginal echography | |
dc.title | Diagnostic features of polycystic ovary syndrome | |
dc.type | Review |